Bcl-6

Bcl-6

A protein that marks germinal center-cell differentiation and regulates lymphocyte differentiation and immune response. Bcl-6 gene rearrangements and Bcl-6 protein expression are frequent in nodular lymphocyte-predominant Hodgkin lymphoma and suggest a germinal center-derived B-cell origin for Barrett esophagitis.
See also: Barrett epithelium, Barrett syndrome.
Farlex Partner Medical Dictionary © Farlex 2012

Bcl-6

A 79-kDa POZ/zinc finger transcriptional repressor and proto-oncogene that maps to chromosome 3q27, which plays a role in B cell activation and proliferation within the germinal centre, and thus is a marker for germinal centre cells and germinal centre lymphomas, especially those lacking gene rearrangements.

Normal expression
Bcl-6 represses lymphocyte activation genes, including blimp-1, which plays a role in plasma cell differentiation. Bcl-6 may thus trigger malignant transformation by inhibiting terminal plasma cell differentiation.

Abnormal expression
Bcl-6 overexpression delays progression through the S phase of the cell cycle/apoptosis, and is present in one third of diffuse large B cell lymphomas
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Of note, the most widely used immunohistochemistry method is the Hans algorithm, which is based on a few markers, that is, 2 GCB markers, CD10 and BCL-6, and 1 activation marker, MUM1.[sup][17]
Also, restoration of miR-127 significantly inhibits growth, induces apoptosis, and reduces migration and invasion of BC cells by targeting pro-oncogene (BCL-6).
This follicular homing process is directed by Bcl-6, which coordinates the downregulation of T cell zone homing C-C chemokine receptor type 7 (CCR7) in parallel with the upregulation of B cell region homing C-X-C chemokine receptor 5 (CXCR5) [8-12].
The latter response may be via its association with the transcriptional repressor BCL-6, which is released upon activation of PPAR[beta]/[delta] [15].
(3) Further work led to the confirmation that the expression of immunohistochemical markers of cell differentiation (CD10, Bcl-6 and MUM1) can be used to determine the GC and non-GC subtypes of DLBCL, and predict survival similar to the cDNA microarray.
Coexpression of CD10 and BCL-6 has been used as a marker of presumptive germinal center origin and has also been suggested to have prognostic implications, but this remains controversial.
During the study, researchers identified a molecule called heat shock protein 90 (Hsp90) that play a vital role in functioning of a protein called BCL-6, known to drive the activity of lymphoma tumour cells.
While there is tumor individuality, the neoplastic cells usually show a B cell phenotype (CD19, CD20, CD22, CD79a) with coexpression of CD10 and CD43; they also express bcl-2 and bcl-6 and demonstrate light-chain (kappa or lambda) restriction.
bcl-6 gene rearrangement appears to play a role in the pathogenesis of FL, and like with diffuse large B-cell lymphoma, it may correlate with a favorable prognosis.